

Real-world effectiveness of a community-based multicomponent maternal smoking cessation program in preventing low birthweight deliveries: Findings from the CTPP cohort

Syed D. Ahmed¹, Anne Berit Petersen^{1,2,3}, Anna P. Nelson¹, Margarita Martinez¹, David Shavlik¹, Bryan T. Oshiro⁴, Pramila N. Singh³

ABSTRACT

INTRODUCTION The effect of smoking cessation during pregnancy on preventing adverse birth outcomes has been shown in studies of US birth certificate data, and in other nations. There is a paucity of data to optimize community-based maternal tobacco cessation programs to improve birth outcomes. Our objective is to evaluate the real-world effectiveness of a multi-component, community-based maternal smoking cessation program in preventing adverse infant outcomes using components of known efficacy.

METHODS The Comprehensive Tobacco Treatment Program (CTTP) was a state-funded maternal tobacco smoking cessation program serving pregnant women in San Bernardino County, California, the largest county in the contiguous US. CTTP used a six-to-eight-week behavioral intervention with components of known efficacy (i.e. incentives, biomarker testing, feedback, and motivational interviewing). We conducted a retrospective cohort study of the 1402 pregnant women enrolled in CTTP during 2012–2019. We conducted a multivariable logistic regression analysis with adverse infant outcomes [premature birth (PTB), low birthweight (LBW), and NICU admission] as the dependent variables, abstinence achieved during [prolonged abstinence (PA) through weekly urinary cotinine tests] or after the program [self-reported point prevalence abstinence (PPA)] as the main effect exposures, and pertinent confounders.

RESULTS We found that PA during the program significantly decreased the odds of LBW (OR=0.67; 95% CI: 0.47–0.96, $p=0.03$), and this association remained for self-report of PPA at 2–4 months after the program (OR=0.70; 95% CI: 0.54–0.90, $p=0.006$), and six months after the program (OR=0.65; 95% CI: 0.47–0.90, $p=0.01$). Similar, albeit weaker, trends were found for PTB (OR=0.80). In these models, older age, early trimester at enrollment, and African American/Black ethnicity also trended toward higher rates of LBW and PTB.

CONCLUSIONS Abstinence achieved during a multi-component behavioral smoking cessation intervention program using components of known efficacy, significantly reduced low birthweight deliveries in a multi-ethnic population.

AFFILIATION

1 School of Public Health, Loma Linda University, Loma Linda, United States

2 School of Nursing, Loma Linda University, Loma Linda, United States

3 Transdisciplinary Tobacco Research Program, Loma Linda University Cancer Center, Loma Linda, United States

4 Department of Gynecology and Obstetrics, Riverside University Health System, Moreno Valley, United States

CORRESPONDENCE TO

Anne Berit Petersen. School of Nursing, Loma Linda University, Loma Linda, United States

E-mail: abpetersen@llu.edu

ORCID iD: <https://orcid.org/0000-0001-6370-9576>

KEYWORDS

maternal smoking, preterm birth, neonate, low birth weight, NICU admission

Received: 11 June 2025

Revised: 3 September 2025

Accepted: 6 September 2025

INTRODUCTION

Maternal smoking is causally linked to adverse birth outcomes such as preterm

birth, low birthweight, small-for-gestational age, neonatal intensive care unit (NICU) admissions, and infant mortality¹. Mechanisms underlying this effect include fetal hypoxia, toxins in smoke leading to insufficient nutrient availability, teratogenic effects, DNA damage, reduced fetal growth, and an increased risk of congenital abnormalities². Although smoking during pregnancy decreased from 2016 to 2022 in the US³, the current rates remain highest among women who are younger, report less than 12 years of education⁴, experience multiple domains of stress before and during gestation⁵, reside in rural areas^{6,7}, and/or report indicators of poverty and/or participation in federal assistance programs⁵. By race/ethnicity, smoking during pregnancy is highest in women identifying as American Indian/Alaskan Native, non-Hispanic White, and African American/Black³.

The association between maternal smoking cessation (self-directed, enrollment in a smoking cessation program) and adverse infant outcomes has been shown in several large cross-sectional studies of US birth certificate data⁸. Using US National Center for Health Statistics data from states recording smoking cessation data on the birth certificate, Soneji et al.⁹ found that maternal smoking cessation was associated with lower rates of pre-term birth among 25233503 expectant mothers. In an analysis of the CDC Pregnancy Risk Assessment and Monitoring System (PRAMS) data from 203437 birth certificates, Xie et al.⁵ showed that smoking cessation reduced the prevalence of preterm birth and small-for-gestational age to levels found among non-smokers. These trends that identify maternal smoking cessation as a cost-effective method to improve birth outcomes, are also evident in the global data¹⁰. There is, however, a paucity of data on optimizing specific components of known efficacy in a maternal smoking cessation program for the purpose of improving maternal and child outcomes¹¹. A few studies have shown the efficacy of financial incentive-based maternal cessation programs for the prevention of low birthweight¹².

In this report, we focus on the Comprehensive Tobacco Treatment Program (CTTP) – a state-funded (First 5 CA.gov) multi-component smoking cessation program at Loma Linda University Health that served San Bernardino County, California, during

2012–2019. San Bernardino County is, by land area, the largest county in the US with a multi-ethnic population of over two million; infant mortality rates in the county have long followed health disparity trends by factors such as race/ethnicity and poverty¹³. The programmatic approach of CTTP was a behavioral intervention (about 8 weeks) delivered in a group format (classroom setting) by health educators, and used intervention components of known efficacy (i.e. incentives, biomarker testing, feedback, and motivational interviewing). During a program evaluation of CTTP in 2020, the data from all 1402 participants were analyzed as a retrospective cohort study that we have described in detail¹⁴. The overall aim of the present study is to examine whether achieving abstinence during or after the multi-component CTTP behavioral intervention decreased the rate of selected adverse infant outcomes at delivery [preterm birth (PTB), low birthweight (LBW), NICU admissions].

METHODS

The methods to assemble and analyze the CTTP cohort data have been extensively described by Petersen et al¹⁴. Here, we briefly summarize the cohort, the outcomes, main effect exposures, confounder variables, and statistical methods.

CTTP cohort

All program participants (2012–2019) of the study were enrolled in the CTTP cohort (n=1402). To participate in the program, a participant needed to be pregnant and willing to participate in a maternal smoking cessation program. Participants were recruited from a county-wide referral network maintained by two health educators and a program coordinator at CTTP. Referral sites included outpatient clinics, hospitals, and rehabilitation facilities of San Bernardino County. Tobacco use was screened according to standardized prenatal protocols¹⁵. Self-enrollment was also available and publicized via flyers located at Women, Infant, Children (WIC) offices of the public health department, community events, and health fairs. The Loma Linda University Health Institutional Review Board approved (by determination) the secondary analysis study protocol (IRB # 5190418).

CTTP multi-component behavioral smoking cessation program

The program was a six-to-eight-week smoking cessation intervention for pregnant women residing in San Bernardino County. The program incorporated weekly in-person sessions that included cotinine-verified abstinence testing, motivational interviewing, personalized quit plans, and education on the risks of smoking tobacco. Incentives such as diapers and xylitol gum were provided for each cotinine-negative week to encourage adherence. Two health educators (Bachelor's or Master's level perinatal health educators) delivered individualized counseling using the ACOG 5As framework, along with screening for depression, alcohol, and substance use, with referrals as needed¹⁶. Follow-up for all participants occurred through telephone appointments at 2–4 months and 6 months after the program administration. This telephone appointment was also used to assess current abstinence and offer relapse support if necessary.

CTTP outcomes

Dependent variables include PTB, LBW, NICU admission, and a combined adverse outcome variable. PTB was classified as a birth occurring before 37 weeks of gestation¹⁷. As per World Health Organization guidelines (WHO), LBW was defined as a neonate weighing less than 2500 g at birth¹⁸. NICU admission was assessed by the health educators during follow-up appointments after program administration. The combined adverse outcome was computed as a composite variable indicating the occurrence of any one of the adverse outcomes (PTB, LBW, NICU admission).

CTTP main effect variables and pertinent confounders

A main effect exposure variable for prolonged abstinence (PA) during the behavioral intervention program was defined as completing the program with six to eight consecutive weeks of cotinine-verified abstinence assessed as urinary cotinine. After the program administration, all subjects (completers, non-completers) were offered a telephone appointment support during which point prevalence abstinence (PPA) from tobacco was assessed by self-report. PPA was assessed at 2–4 months and 6 months after program administration and is also used as a main

effect exposure variable.

Pertinent confounders include self-reported (by interview) age at enrollment, trimester at enrollment, number of cigarettes smoked at enrollment, and race/ethnicity. Household smoking was measured from a self-reported (by participant interview) list of household members (i.e. spouse, partner, family member, roommate) who smoke cigarettes.

Statistical analysis

Descriptive statistics of the cohort have been published previously¹⁴ and, in this article, we provide a cohort profile by level of adverse birth outcome. Prevalences and means are given with asymptotic 95% confidence intervals. Differences by levels of adverse birth outcome are assessed by contingency table methods (i.e. chi-squared) or, for continuous variables, by independent sample t-tests.

The relation between maternal smoking cessation and adverse infant outcomes was assessed in logistic regression models. In each of the models an abstinence measure (PA achieved at program completion, PPA at 2–4 months after the program, PPA at 6 months after the program) was the main effect, and the dependent variables were adverse infant outcomes (PTB, LBW, NICU admission). Pertinent confounders were tested by a change of estimate approach¹⁹. Model fit was tested using the Hosmer-Lemeshow test for continuous variables and log likelihood ratio test for indicator variables¹⁹.

Missing values were imputed using well-established methods for multiple imputation from Rubin²⁰. In Supplementary file Table 1, we show that the independent variables in the model have rates of missingness <10%. The dependent variables did have rates of missingness in the range of 45–53% and this became the rationale to use multiple imputation that can produce robust estimates at this rate of missingness^{19,20}. We used PROC MI and PROC MIANALYZE in SAS 9.4 (Cary, NC) for the multiple imputation²¹. We found good convergence and stable means and standard deviations at 20 burn-in iterations, and 20 imputed data sets. Additionally, we did a sensitivity analysis without multiple imputation and did not find a substantive difference in the main findings. Overall, all analyses were conducted using SAS 9.4 (Cary, NC).

Table 1. Selected characteristics of the Comprehensive Tobacco Treatment Program cohort enrolled during 2012–2019, by birth outcome category (N=1402)

Characteristics	Adverse birth outcomes		p*
	Yes %	No %	
Age at enrollment (years)	27.8	27.4	0.30
Number of cigarettes smoked per day at enrollment	1.6	1.4	0.33
Trimester at enrollment			0.04
First	7.4	5.6	
Second	36.6	27.6	
Third	56	66.8	
Race/Ethnicity			0.02
African American/Black	22.3	16.0	
White	16.6	28.5	
Hispanic/Latino	53.7	46.6	
Native American/Alaskan Native	1.1	0.4	
Asian/Pacific Islander	1.7	2.5	
More than one ethnicity	4.6	5.9	
Household smoking			0.29
Yes	53.0	47.0	
No	49.0	51.0	

*The p-values for comparisons for continuous variables were done with an independent sample t-test and for categorical variables, a chi-squared test.

RESULTS

Descriptive statistics of the CTTTP cohort (n=1420) have been previously reported¹⁴. Briefly, the mean age of the pregnant women of the cohort is 26.8 (SD=5.8) years, the mean gestational weeks at delivery was 38.8 (SD=3.2), and the most common race/ethnicity was Hispanic/Latina (42.9%). Also, we have previously reported that 40.1% of the cohort achieved prolonged abstinence (PA) as defined by testing negative (urinary cotinine) during each week of their enrollment in a completed program offering of the CTTTP²².

In Table 1, we report pertinent characteristics of the cohort by subgroup of experiencing adverse birth outcomes [low birthweight (LBW), pre-term birth (PTB), admission of the neonate to the neonatal intensive care unit (NICU)]. These data show no substantial differences by age at enrollment and cigarettes smoked per day at enrollment. Adverse birth outcomes were more prevalent in women who enrolled in CTTTP during the first and second trimesters, and also more prevalent in African American/Black women. The prevalence of all adverse birth outcomes was 27% and for individual outcomes was 8% for low birthweight, 14% for pre-term birth, and 14% for NICU admissions. Notably, 52% of the

Figure 1. Multivariable odds ratios of pregnant participants in the Comprehensive Tobacco Treatment Program who achieved a significant (*p<0.05; **p<0.01) decrease in odds of low birthweight after achieving 8 weeks of prolonged abstinence (PA) during the program, and point prevalence abstinence (PPA) at either 2–4 months or 6 months after the program (N=1420)




Table 2. Multivariable logistic regression models for low birthweight and pre-term birth outcomes, an abstinence main effect, and five confounders from the Comprehensive Tobacco Treatment Program cohort (N=1402)

Variables	Low birth weight OR (95% CI)			Pre-term birth OR (95% CI)		
	Model 1	Model 2	Model 3	Model 1	Model 2	Model 3
Main effect (abstinence)						
Prolonged abstinence during the program [†]	0.67 (0.47–0.96)*			0.80 (0.63–1.01)		
Point prevalence abstinence 2–4 months after program [†]		0.70 (0.54–0.90)**			0.80 (0.63–1.03)	
Point prevalence abstinence 6 months after program [†]			0.65 (0.47–0.90)**			0.80 (0.62–1.02)
Five Confounders						
1. Age at enrollment	1.02 (0.97–1.08)	1.03 (0.99–1.07)	1.03 (0.99–1.07)	1.06 (1.02–1.11)**	1.07 (1.02–1.11)***	1.07 (1.03–1.11)**
2. Number of cigarettes smoked per day at enrollment	1.03 (0.93–1.13)	1.03 (0.96–1.11)	1.04 (0.97–1.12)	0.99 (0.94–1.05)	0.99 (0.93–1.05)	1.00 (0.94–1.06)
3. Trimester at enrollment						
First	1.08 (0.70–1.67)	1.07 (0.74–1.53)	0.70 (0.36–1.33)	1.31 (1.00–1.72)*	1.30 (0.99–1.70)	1.31 (0.94–1.82)
Second	1 (referent)	1 (referent)	1 (referent)	1 (referent)	1 (referent)	1 (referent)
Third	0.75 (0.58–0.98)*	0.78 (0.61–1.01)	0.79 (0.62–1.02)*	0.61 (0.50–0.75)****	0.61 (0.50–0.76)***	0.62 (0.51–0.76)****
4. Race/Ethnicity						
African American/Black	1.27 (0.93–1.74)	1.26 (0.91–1.73)	1.27 (0.92–1.73)	1.27 (0.98–1.64)	1.30 (0.99–1.71)	1.31 (0.99–1.72)
White	1 (referent)	1 (referent)	1 (referent)	1 (referent)	1 (referent)	1 (referent)
Hispanic/Latino	1.13 (0.81–1.59)	1.14 (0.82–1.57)	1.11 (0.80–1.55)	1.22 (0.95–1.56)	1.26 (1.00–1.59)*	1.25 (0.98–1.59)
Native American	1.36 (0.50–3.70)	1.36 (0.48–3.89)	1.42 (0.49–4.05)	-	-	-
Asian/Pacific Islander	-	-	-	0.65 (0.24–1.73)	0.72 (0.27–1.95)	0.72 (0.26–1.96)
More than one ethnicity	1.46 (0.85–2.49)	1.45 (0.87–2.42)	1.47 (0.88–2.45)	0.98 (0.63–1.51)	0.97 (0.61–1.55)	0.98 (0.62–1.55)
5. Household member(s) smoking						
Yes	1.21 (0.95–1.55)	1.20 (0.96–1.52)	1.20 (0.95–1.52)	1.13 (0.96–1.34)	1.13 (0.94–1.36)	1.14 (0.95–1.37)
No	1 (referent)	1 (referent)	1 (referent)	1 (referent)	1 (referent)	1 (referent)

Model 1 includes prolonged abstinence as a main effect plus five confounders; Model 2 only includes point prevalence abstinence at 2–4 months as a main effect plus five confounders; Model 3 only includes point prevalence abstinence at 6 months as a main effect plus five confounders. *p<0.05. **p<0.01. ***p<0.001. ****p<0.0001. † Testing negative for urinary cotinine during each week of enrollment in the completed program. ‡ Self-report of not smoking during the past seven days. "-" indicates insufficient subjects to compute a point estimate.

CTTP cohort lived in a home with household smoking.

We conducted a multivariable logistic regression analyses with: 1) specific adverse birth outcomes (LBW, PTB, NICU admissions) as the outcome variable; 2) prolonged abstinence (PA) during or point prevalence abstinence (PPA) at 2–4 months and at 6 months after the program, as the main effect exposure variables; and 3) confounders for age at enrollment, cigarettes smoked per day at enrollment, trimester at enrollment, and race/ethnicity. We note that associations between PA and birth outcomes are longitudinal since CTTP completion occurred during gestation. The odds ratios linking PPA at 2–4 months and 6 months to birth outcomes are more cross-sectional in nature since these measures often occurred after delivery.

In Table 2 and Figure 1, we provide the findings from these models where LBW or PTB was the outcome variable. We found a significant decrease in the odds of LBW for PA (OR=0.67; 95% CI: 0.47–0.96), PPA at 2–4 months (OR=0.70; 95% CI: 0.54–0.90), and PPA at 6 months (OR=0.65; 95% CI: 0.47–0.90). In these models, third-trimester enrollments in CTTP were about 30% less likely to result in a LBW delivery, and African American/Black mothers were about 27% more likely to experience a LBW delivery. Similar, albeit weaker, trends were found linking PA and PPA to PTB (Table 2). For NICU admission (not shown), no strong or significant association was found with PA or PPA.

We also ran models (not shown) where we combined all birth outcomes into an Adverse Birth Outcome (LBW, PTB, or NICU admission) dependent variable. We found no significant associations for PA or PPA.

DISCUSSION

Our evaluation of the CTTP cohort indicated that prolonged abstinence (PA) – achieved by completing weekly negative cotinine tests throughout the program administration – significantly decreased the odds of low birthweight (LBW), and this association remained for point prevalence abstinence (PPA) at 2–4 months and 6 months after the program (Figure 1). Slightly weaker and non-significant associations were found between the abstinence measures (PA, PPA) and preterm birth (PTB), and the association with NICU admissions was close to the null.

Taken together, our findings show that a multi-component intervention for pregnant women who

smoke cigarettes can significantly decrease low birthweight deliveries. The CTTP intervention uses components of known efficacy, such as financial incentives^{12,23}, biomarker testing²⁴, biofeedback²³, and motivational interviewing²³. Also, as shown in a Cochrane review of effective maternal smoking cessation interventions, CTTP used a high frequency of counseling sessions tailored to maternal smoking cessation: 6–8 weekly contacts (1 hour of a group class) and telephone follow-up that continued post-partum²³. Concordant with the multi-component CTTP approach, the Cochrane review concludes from the evidence that the best results come from combining financial incentives with a higher frequency of counseling sessions²³.

Preventing low birthweight and pre-term birth through smoking cessation: The San Bernardino County experience

The CTTP cohort provides insight into the efficacy of a multi-component maternal smoking cessation program in a multi-ethnic county (52% Hispanic/Latino, 24% White, 9% Asian, 9% African American/Black, 4% more than one race, <1% American Indian/Alaskan Native, <1% Pacific Islander). This is important since smoking during pregnancy disproportionately affects American Indian/Alaskan Native, non-Hispanic White, and African American/Black communities.

Our group has previously reported that an analysis of the birth certificate data from San Bernardino County indicated that for every 35 pregnant women who quit cigarette smoking, one pre-term birth was prevented²⁵. From these data, we estimated that half of the pregnant smokers in the county who did not quit smoking during pregnancy on their own enrolled in CTTP²⁵ – indicating excellent outreach. Moreover, a 40.1% abstinence rate was achieved by CTTP²². Taken together, our findings from these analyses indicate that the CTTP approach of combining excellent outreach with intervention components of known efficacy can significantly reduce important adverse birth outcomes such as low birthweight.

Our findings from CTTP are concordant with at least one study that used a similar multi-component approach to maternal smoking cessation and related abstinence to adverse birth outcomes. The ‘Baby and Me Tobacco Free’ (BMTF) was first designed and

implemented in New York in 2011 and since then has been implemented in 21 states²⁶. BMTF incorporates components of financial incentives, biofeedback through carbon monoxide testing, and motivational interviewing (four sessions). In Colorado, BMTF involved a data linkage with the PRAMS study and thus was able to relate abstinence achieved in the program to adverse birth outcomes. Among 2231 participants in BMTF, Polinski et al.¹² found that BMTF enrollees had a significantly lower risk of PTB, LBW, and NICU admissions relative to the 16739 pregnant smokers in the control sample from PRAMS who did not enroll in BMTF.

Limitations

A number of limitations of this analysis of CTPP data need to be discussed. The CTPP cohort may not have had statistical power to detect effects with all birth outcomes (PTB, LBW, NICU admissions). This may explain why we only found a significant association with LBW as compared to the BMTF analyses of over eighteen thousand women¹². In CTPP we have previously reported that despite having excellent outreach, we did have a high rate of dropout¹⁴. We have posited that one reason for the dropout rate is the travel time to a program run in a fixed classroom setting. Our current work involves adding a home visit/televisit approach to the CTPP model. Also, our birth outcomes are self-reported and this may introduce bias. Lastly, it is important to note that since CTPP data are from 2012–2019, we did not have enough exposure to e-cigarettes or legalized cannabis that is occurring in the present-day pregnant women. E-cigarette and cannabis use patterns (exclusive, dual user) need consideration in the design of future interventions.

CONCLUSIONS

Our findings from a multi-ethnic sample of 1402 pregnant women who smoked cigarettes during pregnancy indicate that abstinence achieved during a multi-component maternal smoking cessation program using components of known efficacy significantly reduced low birthweight. We were able to control for important confounders in the analysis (age, nicotine dependence at enrollment, trimester at enrollment, race/ethnicity, and household members who smoke)

and demonstrate the impact of a single-site maternal smoking cessation program serving the largest county in the US. Our findings need confirmation in larger prospective samples that also consider current e-cigarette and cannabis exposure among pregnant women in these communities.

REFERENCES

1. Banderali G, Martelli A, Landi M, et al. Short and long term health effects of parental tobacco smoking during pregnancy and lactation: a descriptive review. *J Transl Med.* 2015;13:327. doi:[10.1186/s12967-015-0690-y](https://doi.org/10.1186/s12967-015-0690-y)
2. Ingvarsson RF, Bjarnason AO, Dagbjartsson A, Hardardottir H, Haraldsson A, Thorkelsson T. The effects of smoking in pregnancy on factors influencing fetal growth. *Acta Paediatr.* 2007;96(3):383–386. doi:[10.1111/j.1651-2227.2007.00103.x](https://doi.org/10.1111/j.1651-2227.2007.00103.x)
3. QuickStats: Percentage of Women Who Smoked* Cigarettes During Pregnancy, by Race and Hispanic Origin† - National Vital Statistics System, United States, 2016 and 2022. *MMWR Morb Mortal Wkly Rep.* 2023;72(50):1355. doi:[10.15585/mmwr.mm7250a5](https://doi.org/10.15585/mmwr.mm7250a5)
4. Azagba S, Manzione L, Shan L, King J. Trends in smoking during pregnancy by socioeconomic characteristics in the United States, 2010–2017. *BMC Pregnancy Childbirth.* 2020;20(1):52. doi:[10.1186/s12884-020-2748-y](https://doi.org/10.1186/s12884-020-2748-y)
5. Xie S, Monteiro K, Gjelsvik A. The association between adverse birth outcomes and smoking cessation during pregnancy across the United States-43 States and New York City, 2012–2017. *Arch Gynecol Obstet.* 2023;308(4):1207–1215. doi:[10.1007/s00404-022-06792-x](https://doi.org/10.1007/s00404-022-06792-x)
6. Pilehvari A, Chipoletti A, Krukowski R, Little M. Unveiling socioeconomic disparities in maternal smoking during pregnancy: a comprehensive analysis of rural and Appalachian areas in Virginia utilizing the multi-dimensional YOST index. *BMC Pregnancy Childbirth.* 2024;24(1):828. doi:[10.1186/s12884-024-07032-7](https://doi.org/10.1186/s12884-024-07032-7)
7. Masud N, Hamilton W, Tarasenko Y. Prevalence of cigarette smoking, e-cigarette use, and dual use among urban and rural women during the peripartum period, PRAMS 2015–2020. *Public Health Rep.* 2024;139(6):708–716. doi:[10.1177/00333549241251982](https://doi.org/10.1177/00333549241251982)
8. Aysar TS, McLeod H, Jackson L. Health outcomes of smoking during pregnancy and the postpartum period: an umbrella review. *BMC Pregnancy Childbirth.* 2021;21(1):254. doi:[10.1186/s12884-021-03729-1](https://doi.org/10.1186/s12884-021-03729-1)
9. Soneji S, Beltrán-Sánchez H. Association of maternal cigarette smoking and smoking cessation with preterm birth. *JAMA Netw Open.* 2019;2(4):e192514. doi:[10.1001/jamanetworkopen.2019.2514](https://doi.org/10.1001/jamanetworkopen.2019.2514)
10. Hofmeyr GJ, Black RE, Rogozińska E, et al. Evidence-based antenatal interventions to reduce the incidence of small vulnerable newborns and their associated poor outcomes. *Lancet.* 2023;401(10389):1733–1744.

- doi:[10.1016/S0140-6736\(23\)00355-0](https://doi.org/10.1016/S0140-6736(23)00355-0)
11. Connolly N, Kelly D, O'Donnell P, Hyde S. Effectiveness of smoking cessation interventions in pregnant women attending primary care: a scoping review. *BJGP Open*. 2024;8(3):1-8. doi:[10.3399/BJGPO.2023.0185](https://doi.org/10.3399/BJGPO.2023.0185)
 12. Polinski KJ, Wolfe R, Peterson A, et al. Impact of an incentive-based prenatal smoking cessation program for low-income women in Colorado. *Public Health Nurs*. 2020;37(1):39-49. doi:[10.1111/phn.12682](https://doi.org/10.1111/phn.12682)
 13. Nanyonjo RD, Montgomery SB, Modeste N, Fujimoto E. A secondary analysis of race/ethnicity and other maternal factors affecting adverse birth outcomes in San Bernardino County. *Matern Child Health J*. 2008;12(4):435-441. doi:[10.1007/s10995-007-0260-x](https://doi.org/10.1007/s10995-007-0260-x)
 14. Petersen AB, Ogunrinu T, Wallace S, Yun J, Belliard JC, Singh PN. Implementation and outcomes of a maternal smoking cessation program for a multi-ethnic cohort in California, USA, 2012-2019. *J Community Health*. 2022;47(2):257-265. doi:[10.1007/s10900-021-01042-8](https://doi.org/10.1007/s10900-021-01042-8)
 15. Grangé G, Berlin I, Bretelle F, et al. Smoking and smoking cessation in pregnancy. Synthesis of a systematic review. *J Gynecol Obstet Hum Reprod*. 2020;49(8):101847. doi:[10.1016/j.jogoh.2020.101847](https://doi.org/10.1016/j.jogoh.2020.101847)
 16. US Preventive Services Task Force. Interventions for tobacco smoking cessation in adults, including pregnant persons: US preventive services task force recommendation statement. *JAMA*. 2021;325(3):265-279. doi:[10.1001/jama.2020.25019](https://doi.org/10.1001/jama.2020.25019)
 17. Quinn JA, Munoz FM, Gonik B, et al. Preterm birth: case definition & guidelines for data collection, analysis, and presentation of immunisation safety data. *Vaccine*. 2016;34(49):6047-6056. doi:[10.1016/j.vaccine.2016.03.045](https://doi.org/10.1016/j.vaccine.2016.03.045)
 18. Cutland CL, Lackritz EM, Mallett-Moore T, et al. Low birth weight: case definition & guidelines for data collection, analysis, and presentation of maternal immunization safety data. *Vaccine*. 2017;35(48)(pt A):6492-6500. doi:[10.1016/j.vaccine.2017.01.049](https://doi.org/10.1016/j.vaccine.2017.01.049)
 19. Rothman KJ, Greenland S, Lash TL. *Modern epidemiology*. 3rd ed. Lippincott Williams & Wilkins; 2008.
 20. Rubin DB. *Multiple Imputation for Nonresponse in Surveys*. John Wiley & Sons; 1987. doi:[10.1002/9780470316696](https://doi.org/10.1002/9780470316696)
 21. Yuan YC. *Multiple Imputation for Missing Data: Concepts and New Development*. Statistics and Data Analysis. Accessed September 3, 2025. <https://support.sas.com/resources/papers/proceedings/proceedings/sugi25/25/st/25p267.pdf>
 22. Wiles SD, Lee JW, Nelson A, Petersen AB, Singh PN. Racial/ethnic disparities impact the real-world effectiveness of a multicomponent maternal smoking cessation program: findings from the CTPP cohort. *Matern Child Health J*. 2023;27(11):2038-2047. doi:[10.1007/s10995-023-03753-x](https://doi.org/10.1007/s10995-023-03753-x)
 23. Chamberlain C, O'Mara-Eves A, Porter J, et al. Psychosocial interventions for supporting women to stop smoking in pregnancy. *Cochrane Database Syst Rev*. 2017;2(2):CD001055. doi:[10.1002/14651858.CD001055.pub5](https://doi.org/10.1002/14651858.CD001055.pub5)
 24. Sloan M, Campbell KA, Bowker K, et al. Pregnant women's experiences and views on an "opt-out" referral pathway to specialist smoking cessation support: a qualitative evaluation. *Nicotine Tob Res*. 2016;18(5):900-905. doi:[10.1093/ntr/ntv273](https://doi.org/10.1093/ntr/ntv273)
 25. Batech M, Tonstad S, Job JS, et al. Estimating the impact of smoking cessation during pregnancy: the San Bernardino County experience. *J Community Health*. 2013;38(5):838-846. doi:[10.1007/s10900-013-9687-8](https://doi.org/10.1007/s10900-013-9687-8)
 26. Gadomski A, Adams L, Tallman N, Krupa N, Jenkins P. Effectiveness of a combined prenatal and postpartum smoking cessation program. *Matern Child Health J*. 2011;15(2):188-197. doi:[10.1007/s10995-010-0568-9](https://doi.org/10.1007/s10995-010-0568-9)

CONFLICTS OF INTEREST

The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. The authors declare that they have no competing interests, financial or otherwise, related to the current work. A.B. Petersen, B.T. Oshiro and P.N. Singh report that since the initial planning of the work, this work has been supported by the Tobacco-related Disease Research Program award T32KT4784 from the University of California [Grant awarded to Loma Linda University (Petersen PI; Singh co-I)]. A.B. Petersen and P.N. Singh report that in the past 36 months they have received NIH grant 5R01TW005964-10, Building Capacity for Tobacco Control Research in Asia (Petersen co-I; Singh PI). P.N. Singh has received consulting fees as a Westat Consultant to review proposals for the National Household Survey on Drug Abuse for NIH, and has also received payment as a NIH Study Section Reviewer (HDD, IPTA study sections). B.T. Oshiro reports that in the past 36 months he has received grants or contracts from the First 5 Riverside - HeRCARe Services for High-Risk Pregnancy Care.

FUNDING

Data collection was funded by First 5 CA.gov (San Bernardino). Initial data analysis and reporting by PS was funded by Grant HHSN 267200700021 from NICHD/Department of Health and Human Services (National Children's Study Award to University of California, Irvine, and sub-award to Loma Linda University and California State University San Bernardino). ABP, PS, and BO conducted further analysis of the CTPP cohort for this article under a Tobacco-related Disease Research Program award T32KT4784 from the University of California.

ETHICAL APPROVAL AND INFORMED CONSENT

The Loma Linda University Health Institutional Review Board approved (by determination) the secondary analysis study protocol (Approval number: IRB # 5190418; Date: 25 October 2019).

DATA AVAILABILITY

The data supporting this research are available from the authors on reasonable request.

AUTHORS' CONTRIBUTIONS

SDA: reviewed the literature, analyzed the data and compiled the manuscript. ABP and APN: reviewed and edited the manuscript. MM and DS: conducted the initial data analysis. BTO: obtained the funding for CTPP and edited the manuscript. PNS: initiated the program evaluation, conducted the data analysis, interpreted the results, edited the manuscript, and provided guidance for the study. All authors read and approved the final version of the manuscript.

PROVENANCE AND PEER REVIEW

Not commissioned; externally peer reviewed.